Taiwan-based digital health startup Health2Sync has entered into a partnership with pharma giant Sanofi with the aim to apply the digital solution provided by Health2Sync in 300 clinics and hospitals nationwide certified by Taiwan Diabetes Shared Care Network over the next three years.
As part of the partnership, Health2Sync will provide patient management software for healthcare professionals...
Over the last few months respiratory health has become a major area of focus within the medical community and beyond, as COVID-19 on takes its toll. However, respiratory conditions have long impacted the American public. In fact, the CDC reports that 19.2 million US adults have asthma.
As in many areas of health, today we are seeing the rise of digital for monitoring and treating respiratory...
Sanofi has announced this week that it is supporting a three-month pilot to facilitate access to an online symptom checker from British company Babylon for people concerned about digestive health issues.
The service can be accessed through the Buscopan and Dulcolax websites, Sanofi’s over the counter digestive health products.
The pharma giant is understood to have launched a similar initiative...
It has been a tumultuous week in the realm of digital health partnerships. It started with word of Proteus Digital Health’s floundering business and failed investment round, which reports say was partially driven by cooling relations between the digital pill maker and its longtime patron Otsuka Pharmaceuticals. A few days later, Sanofi announced a company-wide strategy shift that found Onduo, its...
Sanofi announced a major strategy shift today that will end the pharma’s diabetes and cardiovascular R&D efforts in favor of a reinvigorated focus on growing its immunology and vaccine businesses.
Among the fallout of this new game plan is Onduo, the pharma’s diabetes management joint venture with Verily that the two companies invested $500 million into back in 2016, according to the company’...
Sanofi is merging its real-world data platform with New York startup Aetion’s similar evidence platform to augment its treatment development and deployment efforts, the companies announced today. Sanofi’s DARWIN platform will provide a substantial body of de-identified patient data, which the Aetion Evidence Platform will analyze those information for insights on drug effectiveness, safety and...
It’s been two years since the first software-only digital therapeutic got the FDA greenlight, but the industry is still very much in its infancy and continuing to evolve. New entrances are emerging from the world of health, pharma, tech and finance. As the industry matures, it's grappling with existential questions including regulation, reimbursement models and, as always, the definition of a...
Sanofi has been active in the digital space this week inking two big deals: one with tech company Abbott and the other with digital platform Happify.
The first partnership with Abbott will combine the medtech company’s FreeStyle Libre, a continuous glucose monitoring system, and the pharma giant’s insulin dosing information to create smart pens and insulin titration apps.
Sanofi is currently...
Startups can have a difficult time striking a balance between the fast pace of tech culture and healthcare’s slow-and-steady validation culture.
In part, the culture clash is a West Coast-East Coast divide, with tech giants congregating for the most part in California and hospitals and pharma in the Northeast, according to a panel moderated by CNBC’s Christina Farr at the MassBio Digital Health...
Diving deeper into digital, this quarter the pharma giants have continued to implement new tools to enhance clinical trials, support medication management with technology and partner in developing digital therapeutics.
Onc, a foreign entity to this established industry, pharma executives are now becoming better versed in working with digital health companies and sharing the lessons they've...
